| Summary: | Leishmaniasis is a parasitic disease caused by various species of Leishmania, which affects
millions of people worldwide. Current treatments for leishmaniasis often present adverse
effects and may not be effective against every Leishmania strain or form of the disease.
Therefore, it is essential to explore new therapeutic approaches to combat the parasite. In this
study, we focused on the PeBoW complex proteins homologous in Leishmania, which is
involved in ribosomal biogenesis and plays a critical role in cancer development in mammalian
cells. Recently, a homologue of the oncogene PES1 was found in Leishmania major, which
plays a crucial role in parasite infectivity. Given this, we analyzed the possibility of using other
PeBoW complex partner genes in Leishmania as therapeutic targets for leishmaniasis treatment.
Specifically, our investigation aimed to characterize the partner WDR12 homologous in
Leishmania infantum (LmjWDR12) as new therapeutic approach.
|
|---|